Mr. Joshua Bartch reports

NOVERIS ANNOUNCES NEW CHIEF STRATEGY OFFICER

Noveris Health Sciences Inc. has appointed Jason Birmingham as chief strategy officer of the company, effective immediately.

Mr. Birmingham has over 33 years of experience as an entrepreneurial executive and consulting professional. Mr. Birmingham brings to the company hands-on experience in domestic and international private and public company start-ups.

Since April, 1999, he has run his own consulting business, and has been involved with many companies in the capacities of founder/principal, senior officer, director and/or financier. He brings experience with project generation, deal negotiation and acquisition, corporate structuring and strategic planning, private and public company finance and regulatory compliance, public and investor relations marketing, and board and committee activities. Industries served include resource exploration/exploitation, technology, hospitality and agri-business. He has been a director of several publicly listed companies on the TSX Venture Exchange and Canadian Securities Exchange. His network of contacts within the financial and business community extends across North America and Europe.

Mr. Birmingham completed the Canadian securities course in 1995 and completed the Real Estate Salesperson's submortgage broker's prelicensing course through the Faculty of Commerce and Business Administration at the University of British Columbia in 1996.

About Noveris Health Sciences Inc.

Noveris is a biotechnology company developing the next generation of innovative medications and therapies to address mental health disorders, such as nicotine addiction and posttraumatic stress disorder (PTSD). The core strategy blends advanced technology with an elaborate infrastructure for drug discovery and development. Noveris's dedicated multinational team constantly develops new paths for breakthrough treatment solutions in areas with considerable unmet needs. By collaborating with some of the world's leading specialists, the company aspires to responsibly speed up the development of breakthrough medications to provide patients with safer and more effective treatment solutions. At the same time, Noveris's approach focuses on the next generation of psychedelic medicine by creating innovative compounds with unmatched therapeutic potential through its clinical trial efforts with world-class scientific and regulatory expertise.